Pharmacokinetics of Subcutaneous Low Molecular Weight Heparin (Enoxaparin) in Dogs
- 1 January 2009
- journal article
- Published by American Animal Hospital Association in Journal of the American Animal Hospital Association
- Vol. 45 (6) , 261-267
Abstract
Unfractionated heparin has been the standard heparin used in human and veterinary medicine for its anticoagulation effect; however, it has a complex pharmacodynamic profile that requires close monitoring. Low molecular weight heparins have a more predictable bioavailability, allowing standardized dosing without individual patient monitoring. This project was designed to a) evaluate the pharmacokinetics of the subcutaneous (SC) administration of the low molecular weight heparin, enoxaparin, in dogs using anti-Xa activity as a marker of plasma enoxaparin concentrations and b) to establish the dose necessary to maintain activity within an established target range. Enoxaparin at 0.8 mg/kg SC q 6 hours consistently maintained target levels of anti-Xa activity in normal dogs without evidence of hemorrhagic complications.Keywords
This publication has 24 references indexed in Scilit:
- Heparin and Low-Molecular-Weight HeparinChest, 2004
- Comparison of pharmacokinetic variables for two low-molecular-weight heparins after subcutaneous administration of a single dose to horsesAmerican Journal of Veterinary Research, 2002
- Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic DiseaseAnnals of Internal Medicine, 2001
- Prevention of Venous ThromboembolismChest, 2001
- The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dogCardiovascular Research, 1998
- Enoxaparin (Clexane®, Lovenox®), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulabilityThrombosis Research, 1992
- HeparinNew England Journal of Medicine, 1991
- In Vitro Coagulant and Amidolytic Methods for Evaluating the Activity of Heparin and a Low Molecular Weight Derivative (PK 10169)Seminars in Thrombosis and Hemostasis, 1985
- A new low molecular weight heparin derivative. In vitro and in vivo studiesThrombosis Research, 1983
- Structure of the antithrombin-binding site in heparin.Proceedings of the National Academy of Sciences, 1979